CEACAM5 (CEA) was chosen as a CAR target because of its high expression in neuroendocrine prostate cancer (31), colorectal cancer (32), gastric cancers (33), and small cell cancers of the lung (34). This evidence concerns the gene CEACAM5 and colorectal cancer.